antibodydepend
enhanc
ade
felin
infecti
periton
viru
fipv
infect
studi
felin
alveolar
macrophag
human
monocyt
cell
line
use
mous
neutral
monoclon
antibodi
mab
direct
spike
protein
fipv
even
among
mab
shown
recogn
antigen
site
igg
mab
enhanc
fipv
infect
strongli
wherea
igg
mab
igg
mab
enhanc
infect
even
macrophag
pretreat
mab
wash
inocul
viru
immunofluoresc
flow
cytometr
analysi
macrophag
treat
mab
show
igg
mab
igg
mab
bound
felin
alveolar
macrophag
treatment
igg
mab
protein
decreas
bind
macrophag
parallel
diminish
ade
activ
although
infect
observ
inocul
fipv
human
monocyt
cell
line
cell
fipv
complex
either
igg
mab
igg
mab
caus
infect
cell
shown
express
fc
gamma
receptor
fc
r
ii
bind
mous
igg
igg
respect
result
suggest
enhanc
activ
mab
close
correl
igg
subclass
correl
involv
bind
mab
fc
r
felin
macrophag
felin
infecti
periton
viru
fipv
member
coronaviru
famili
caus
chronic
progress
diseas
natur
host
natur
rout
fipv
infect
unknown
although
cat
experiment
infect
oral
nasal
parenter
administr
fipv
follow
infect
rout
fipv
first
multipli
epitheli
cell
upper
respiratori
tract
intestin
clinic
appar
fip
occur
virus
infect
hohdatsu
et
al
macrophag
monocyt
cross
mucos
barrier
spread
throughout
bodi
cat
gener
macrophag
play
import
role
nonspecif
defens
viral
infect
howev
also
known
virus
bound
antibodi
invad
macrophag
via
fc
region
bound
antibodi
macrophag
fc
gamma
receptor
fc
r
eventu
lead
enhanc
infect
typic
exampl
diseas
call
dengu
hemorrhag
feverdengu
shock
syndrom
antibodi
fipv
also
known
enhanc
fipv
infect
acceler
diseas
onset
cat
follow
experiment
fipv
infect
cat
natur
occur
fipvneutr
antibodi
frequent
develop
fip
rapidli
sever
clinic
sign
seroneg
cat
cat
passiv
immun
antifipv
antibodi
infect
virul
fipv
sever
symptom
observ
die
soon
infect
enhanc
effect
antibodi
fipv
infect
imped
prophylaxi
fip
vaccin
previous
report
vitro
fipv
infect
felin
alveolar
macrophag
enhanc
murin
monoclon
antibodi
mab
peplom
spike
protein
transmembran
protein
fipv
antibodydepend
enhanc
ade
complet
elimin
reduc
pretreat
mab
protein
f
ab
fragment
mab
use
olsen
et
al
support
find
show
enhanc
fipv
infect
primari
felin
periton
macrophag
mous
mab
viral
protein
mani
instanc
virusneutr
mab
shown
strong
ade
activ
suggest
relationship
neutral
activ
ade
activ
hand
corapi
et
al
recogn
differ
immunoglobulin
subclass
adeinduc
fipvneutr
mab
adenon
induc
fipvneutr
mab
show
major
adeinduc
mab
belong
igg
subclass
result
obtain
experi
mous
mab
felin
macrophag
ie
xenogen
combin
mab
macrophag
use
contrast
report
mous
mab
irrespect
whether
subclass
igg
igg
igg
enhanc
infect
mous
homolog
macrophag
dengu
viru
influenza
viru
west
nile
viru
sinc
ade
diseas
caus
fipv
clearli
demonstr
vaccin
cat
varieti
candid
vaccin
specif
understand
ade
fipv
infect
need
especi
import
develop
vaccin
understand
relationship
fipv
neutral
activ
ade
activ
anti
fipv
mab
studi
determin
relationship
immunoglobulin
subclass
ade
activ
fipvneutr
mab
attempt
explor
mechan
ade
fipv
infect
vitro
system
use
mous
mab
felin
alveolar
macrophag
human
monocyt
fipv
strain
use
studi
strain
kindli
provid
dr
c
horzinek
state
univers
utrecht
netherland
passag
two
three
time
felin
fetal
cell
cultur
felin
alveolar
macrophag
collect
anticoronaviru
antibodyneg
adult
cat
cultur
eagl
minimum
essenti
medium
contain
leibovitz
medium
fetal
calf
serum
unit
penicillin
per
ml
tg
streptomycin
per
ml
previous
describ
human
monocyt
cell
line
kindli
provid
dr
j
arikawa
univers
hokkaido
japan
cultur
rpmi
medium
contain
fetal
calf
serum
unit
penicillin
per
ml
tg
streptomycin
per
ml
mab
use
present
studi
recogn
protein
viru
demonstr
immunoblot
mab
abil
neutral
fipv
strain
recogn
two
differ
antigen
site
viral
protein
neutral
titer
indirect
immunoftuoresc
antibodi
titer
immunoglobulin
isotyp
epitop
specif
mab
shown
tabl
cultur
fluid
mabproduc
hybridoma
use
experi
f
ab
mab
fab
mab
f
ab
mab
purchas
medarex
lebanon
nh
mab
mous
igg
antibodi
react
human
r
mab
mous
igg
antibodi
react
human
r
ii
mab
mous
igg
antibodi
react
human
fc
r
iii
mixtur
mab
recogn
peplom
protein
transmembran
protein
nucleocapsid
protein
n
fipv
strain
respect
use
primari
antibodi
mab
ad
acetonefix
fipvinfect
cell
allow
stand
rain
specimen
wash
phosphatebuff
salin
pb
three
time
stain
rabbit
antimous
igg
iga
igm
serum
conjug
fluorescein
isothiocyan
mile
laboratori
napervil
usa
held
wash
pb
mount
glycerol
buffer
observ
fluoresc
microscop
confluent
cell
monolay
plastic
petri
dish
inocul
viru
dilut
specimen
assay
amount
infecti
viru
ml
amount
viru
adsorpt
inocul
cultur
cover
ml
agar
overlay
medium
consist
bacto
agar
minim
essenti
medium
cultur
incub
incub
day
stain
incub
h
second
overlay
medium
contain
neutral
red
infecti
titer
express
plaqueform
unit
pfu
ade
assay
fipv
infect
felin
alveolar
macrophag
perform
two
method
first
method
equal
amount
mab
viral
suspens
allow
react
hohdatsu
et
al
h
inocul
onto
macrophag
second
method
mab
alon
allow
react
macrophag
h
viral
inocul
method
virusinocul
cell
examin
viral
antigen
ifa
use
mixtur
antifipv
mab
incub
percent
ade
determin
follow
formula
rate
ifa
posit
cell
cultur
infect
presenc
mab
b
cultur
infect
absenc
mab
ade
assay
fipv
infect
human
monocyt
cell
line
viru
suspens
allow
react
mab
h
inocul
cell
pellet
cell
inocul
cell
incub
h
allow
viru
adsorpt
wash
hank
balanc
salt
solut
hbss
wash
cell
cultur
h
later
examin
infect
fipv
antigen
ifa
time
level
infecti
viru
cultur
supernat
determin
plaqu
assay
undilut
mab
mixtur
either
one
mab
fipv
ad
x
felin
alveolar
macrophag
held
h
three
wash
hbss
contain
n
cell
allow
react
dilut
fitcconjug
fab
goat
antimous
igg
antibodi
h
wash
three
time
stain
cell
analyz
count
cell
fac
becton
dickinson
co
usa
relationship
ig
subclass
e
activ
investig
b
shown
tabl
shown
fig
despit
fact
e
activ
b
also
determin
inocul
f
p
v
macrophag
pretreat
b
fig
b
whose
subclass
g
g
enhanc
infect
way
case
mixtur
f
p
v
b
inocul
macrophag
contrast
none
subclass
igg
mab
show
ade
activ
fig
result
togeth
shown
fig
clearli
indic
relationship
ig
subclass
mab
ade
activ
bind
mous
antifipv
mab
fc
r
felin
alveolar
macrophag
determin
indirect
immunofluoresc
flow
cytometri
mabtreat
macrophag
figur
show
percentag
posit
stain
cell
macrophag
treat
differ
mab
percentag
stain
macrophag
treat
either
one
igg
mab
low
almost
control
macrophag
treat
hbss
instead
mab
contrast
percentag
stain
macrophag
treat
either
one
igg
mab
distinctli
figur
next
determin
ade
mous
antifipv
mab
f
p
v
infect
h
u
n
cell
f
p
v
alon
mixtur
f
p
v
either
one
mab
inocul
cell
inocul
cell
cultur
h
later
viral
prolifer
assess
ifa
cell
mixtur
antifipv
mab
viru
plaqu
assay
cultur
supernat
tabl
f
p
v
alon
inocul
cell
viral
prolifer
occur
wherea
occur
viru
complex
either
one
mab
inocul
notabl
f
p
v
infect
establish
cell
even
igg
mab
show
e
infect
felin
macrophag
even
though
degre
e
far
less
igg
mab
vitro
studi
use
n
f
p
v
mab
vivo
studi
cat
immun
recombin
vaccinia
viru
express
f
p
v
protein
indic
antibodi
f
p
v
protein
induc
e
f
p
v
infect
studi
show
mab
viru
neutral
activ
caus
intens
e
f
p
v
infect
suggest
epitop
f
p
v
recogn
e
close
relat
viru
neutral
present
studi
e
n
r
e
even
n
g
mous
f
p
v
neutral
mab
shown
recogn
antigen
site
competit
bind
assay
igg
b
igg
b
enhanc
f
p
v
infect
felin
alveolar
c
r
p
h
g
e
fig
igg
mab
enhanc
infect
even
macrophag
pretreat
mab
wash
inocul
viru
fig
therefor
assum
mous
igg
antibodi
bind
fc
r
felin
alveolar
macrophag
wherea
igg
antibodi
confirm
flow
cytometr
analysi
bind
mab
felin
macrophag
fig
addit
found
igg
mab
complex
fipv
bound
macrophag
intens
mab
alon
fig
b
accord
find
ade
fipv
infect
intens
macrophag
infect
former
pathway
virusinocul
latter
macrophag
fig
flow
cytometr
analysi
bind
protein
atreat
igg
mab
macrophag
determin
ade
fipv
infect
treat
mab
reveal
bind
mous
igg
mab
felin
macrophag
ade
activ
fipv
infect
macrophag
mediat
fc
region
mab
fig
sinc
fc
rs
felin
cell
defin
explor
fcmediat
ade
fipv
infect
use
human
cell
fc
rs
well
defin
target
viru
known
three
type
human
fc
r
ie
fc
r
ii
iii
also
shown
fc
r
ii
present
human
macrophag
mous
igg
igg
bind
well
fc
r
ii
respect
human
monocyt
cell
line
cell
use
present
studi
shown
express
fc
r
ii
similar
degre
surfac
reactiv
mab
specif
respect
human
fc
r
fig
fipv
strain
infect
cell
howev
fipv
complex
either
one
mous
antifipv
mab
inocul
onto
cell
distinct
viral
prolifer
observ
notabl
igg
mab
bind
felin
macrophag
caus
ade
fipv
infect
felin
macrophag
caus
viral
prolifer
cell
result
suggest
cell
human
origin
viru
receptor
fipv
fc
rs
ie
fc
r
ii
act
receptor
mous
igg
igg
mab
complex
viru
thu
allow
viru
enter
prolifer
cell
mous
antifipv
igg
mab
devoid
neutral
activ
report
exert
ade
fipv
infect
felin
macrophag
though
ade
activ
igg
mab
far
less
mous
igg
mab
use
present
studi
reason
discrep
studi
studi
mous
antifipv
igg
mab
found
show
ade
fipv
infect
felin
macrophag
clear
follow
possibl
fc
r
mous
igg
express
felin
macrophag
small
number
fc
r
mous
igg
felin
macrophag
low
affin
relat
latter
possibl
cell
human
origin
express
fc
r
ii
similar
level
ade
activ
mous
antifipv
igg
mab
fipv
infect
cell
found
far
weaker
antifipv
igg
mab
also
known
human
igg
igg
weak
affin
fc
r
human
macrophag
one
studi
ade
dengu
viru
infect
mous
macrophag
shown
treatment
macrophag
neuraminidas
increas
affin
fc
r
ii
mous
igg
mab
result
increas
ade
infect
mous
antidengu
viru
igg
mab
might
verifi
similar
experi
fipv
system
taken
result
present
studi
togeth
indic
ade
fipv
infect
mediat
bind
fc
region
antifipv
antibodi
fc
receptor
express
target
cell
fipv
support
find
fipvneutr
mab
could
enhanc
fipv
infect
crandel
felin
kidney
cell
devoid
fc
r
present
studi
howev
explor
ade
fipv
infect
vitro
experi
xenogen
combin
viru
target
antifipv
antibodi
ie
felin
alveolar
macrophag
human
monocyt
cell
mous
antifipv
protein
mab
use
therefor
find
present
studi
could
appli
directli
ade
natur
infect
cat
schultz
et
al
report
two
subclass
felin
igg
howev
biolog
properti
felin
igg
subclass
yet
clarifi
studi
felin
igg
subclass
explor
fc
r
felin
cell
mandatori
igg
subclass
antifipv
antibodi
serum
natur
infect
cat
enhanc
fipv
infect
investig
studi
worthwhil
determin
basic
pathogenesi
fip
develop
vaccin
prevent
fipv
infect
